相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Expression of the neural cell adhesion molecule (CD56) by human myeloma cells
J. DRACH et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2010)
The MMSET protein is a histone methyltransferase with characteristics of a transcriptional corepressor
Jotin Marango et al.
BLOOD (2008)
Prognostic value of immunophenotyping in multiple myeloma:: A study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy
Gema Mateo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Clinicopathological correlates of plasma cell CD56 (NCAM) expression in multiple myeloma
Maria Kraj et al.
LEUKEMIA & LYMPHOMA (2008)
Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14)
M. Hundemer et al.
BONE MARROW TRANSPLANTATION (2007)
Novel RUNX1 isoforms determine the fate of acute myeloid leukemia cells by controlling CD56 expression
Stefan Gattenloehner et al.
BLOOD (2007)
Cyclin D1 induction through IκB kinase β/nuclear factor-κB pathway is responsible for arsenite-induced increased cell cycle G1-S phase transition in human keratinocytes
WM Ouyang et al.
CANCER RESEARCH (2005)
Molecular classification of multiple myeloma:: A distinct transcriptional profile characterizes patients expressing CCND1 and negative for 14q32 translocations
L Agnelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma
PL Bergsagel et al.
BLOOD (2005)
The t(8;21) translocation converts AML1 into a constitutive transcriptional repressor
J Wildonger et al.
DEVELOPMENT (2005)
MYND-less splice variants of AML1-MTG8 (RUNX1-CBFA2T1) are expressed in leukemia with t(8;21)
T Kozu et al.
GENES CHROMOSOMES & CANCER (2005)
The absence of CD56 on malignant plasma cells in the cerebrospinal fluid is the hallmark of multiple myeloma involving central nervous system
H Chang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2005)
Amplification or duplication of chromosome band 21q22 with multiple copies of the AML1 gene and mutation of the TP53 gene in therapy-related MDS and AML
MK Andersen et al.
LEUKEMIA (2005)
Role of RUNX1 in adult hematopoiesis: analysis of RUNX1-IRES-GFP knock-in mice reveals differential lineage expression
RB Lorsbach et al.
BLOOD (2004)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
Prognostic significance of surface markers expressed in multiple myeloma: CD56 and other antigens
N Sahara et al.
LEUKEMIA & LYMPHOMA (2004)
Expression of PAX5 in CD20-positive multiple myeloma assessed by immunohistochemistry and oligonucleotide microarray
P Lin et al.
MODERN PATHOLOGY (2004)
Occurrence of dysregulated oncogenes in primary plasma cells representing consecutive stages of myeloma pathogenesis:: indications for different disease entities
T Rasmussen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2003)
Cyclin D1 overexpression is a favorable prognostic variable for newly diagnosed multiple myeloma patients treated with high-dose chemotherapy and single or double autologous transplantation
S Soverini et al.
BLOOD (2003)
c-maf oncogene dysregulation in multiple myeloma: Frequency and biological relevance
T Rasmussen et al.
LEUKEMIA & LYMPHOMA (2003)
AYL-1A and AML-1B regulation of MIP-1α expression in multiple myeloma
SJ Choi et al.
BLOOD (2003)
In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression
JJ Keats et al.
BLOOD (2003)
Altered mRNA expression of Pax5 and Blimp-1 in B cells in multiple myeloma
ND Borson et al.
BLOOD (2002)
Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma
N Sahara et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
FGFR3 dysregulation in multiple myeloma: frequency and prognostic relevance
T Rasmussen et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
AML1 stimulates G1 to S progression via its transactivation domain
F Bernardin et al.
ONCOGENE (2002)
Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma from monoclonal gammopathy of undetermined significance and lymphomas with plasmacytoid differentiation
SA Ely et al.
AMERICAN JOURNAL OF PATHOLOGY (2002)
Differential expression of CD56 and CD44 in the evolution of extramedullary myeloma
IMS Dahl et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Frequency and prognostic relevance of cyclin D1 dysregulation in multiple myeloma
T Rasmussen et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2001)
Chromosome translocations in multiple myeloma
PL Bergsagel et al.
ONCOGENE (2001)
分享论文
